Q-omics provides the consensus-scored SHB profile across patient tissues and cancer cell-line models. SHB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SHB is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SHB RNA expression shows 16,693 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KICH as cancer lineages where SHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHB survival associations across molecular data types. SHB RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHB RNA expression–survival associations across cancer types. High SHB expression shows unfavorable associations in ACC, SKCM and HNSC, but favorable associations in UCEC, ESCA and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SHB RNA expression.
This table summarizes SHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHB shows lower tumor expression in KICH and higher tumor expression in COAD, THCA, BRCA, STAD and UCEC. The KICH box plot shows higher SHB RNA expression in normal versus tumor tissue (log2 FC = −1.797, t-test p < 0.001).
This table shows molecular features associated with SHB in patient tissues and cancer cell lines. In patient samples, SHB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
